An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.

Trial Profile

An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Servier
  • Most Recent Events

    • 04 Jan 2017 This trial has been discontinued in Spain as per European Clinical Trials Database record.
    • 06 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top